HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 4 (April)

1. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study.
   Lancet, 369(9567): 1107-16. [Abstract] [Full-text]
2. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment.
   Ophthalmology, 114(4): 780-6. [Abstract] [Full-text]
3. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment.
   Ophthalmology, 114(4): 787-93. [Abstract] [Full-text]
4. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.
   J Infect Dis, 195(9): 1345-52. [Abstract] [Full-text]
5. Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis.
   J Infect Dis, 195(9): 1303-10. [Abstract] [Full-text]
6. Progesterone inhibits HIV-1 replication in human trophoblast cells through inhibition of autocrine tumor necrosis factor secretion.
   J Infect Dis, 195(9): 1294-302. [Abstract] [Full-text]
7. Molecular epidemiology of HIV-1 infection and full-length genomic analysis of circulating recombinant form 07_BC strains from injection drug users in Taiwan.
   J Infect Dis, 195(9): 1283-93. [Abstract] [Full-text]
8. HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi.
   J Infect Dis, 195(9): 1278-82. [Abstract] [Full-text]
9. Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection.
   J Infect Dis, 195(9): 1270-7. [Abstract] [Full-text]
10. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania.
    J Infect Dis, 195(9): 1260-9. [Abstract] [Full-text]
11. The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient.
    J Infect Dis, 195(9): 1250-9. [Abstract] [Full-text]
12. Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1).
    J Med Virol, 79(5): 639-46. [Abstract] [Full-text]
13. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus.
    J Med Virol, 79(5): 503-10. [Abstract] [Full-text]
14. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
    J Med Virol, 79(5): 474-82. [Abstract] [Full-text]
15. Knowledge and attitude toward HIV voluntary counseling and testing services among pregnant women attending an antenatal clinic in Sudan.
    J Med Virol, 79(5): 469-73. [Abstract] [Full-text]
16. Major CD4 epitopes involved in anti-CD4 T-cell autoimmunity in HIV-1 patients.
    Vaccine, 25(16): 3192-9. [Abstract] [Full-text]
17. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
    Vaccine, 25(16): 3070-4. [Abstract] [Full-text]
18. Unique features of TRIM5alpha among closely related human TRIM family members.
    Virology, 360(2): 419-33. [Abstract] [Full-text]
19. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Virology, 360(2): 247-56. [Abstract] [Full-text]
20. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
    Virology, 360(2): 329-40. [Abstract] [Full-text]
21. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell.
    Virology, 360(2): 286-93. [Abstract] [Full-text]
22. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
    Virology, 360(2): 294-304. [Abstract] [Full-text]
23. Atomic force microscopy investigation of Mason-Pfizer monkey virus and human immunodeficiency virus type 1 reassembled particles.
    Virology, 360(2): 434-46. [Abstract] [Full-text]
24. In vitro analysis of the effects of mutations in the G-tract of the human immunodeficiency virus type 1 polypurine tract on RNase H cleavage specificity.
    Virology, 360(2): 341-9. [Abstract] [Full-text]
25. Increasing antiretroviral drug access for children with HIV infection.
    Pediatrics, 119(4): 838-45. [Abstract] [Full-text]
26. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.
    Am J Obstet Gynecol, 196(4): 331.e1-7. [Abstract] [Full-text]
27. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.
    Pediatrics, 119(4): e900-6. [Abstract] [Full-text]
28. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.
    Pediatrics, 119(4): e893-9. [Abstract] [Full-text]
29. The impact of anemia on quality of life and healthcare resource utilization in patients with HIV/AIDS receiving antiretroviral therapy.
    Curr Med Res Opin, 23(4): 803-10. [Abstract] [Full-text]
30. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings.
    Clin Infect Dis, 44(9): 1245-8. [Abstract] [Full-text]
31. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India.
    Clin Infect Dis, 44(9): 1235-44. [Abstract] [Full-text]
32. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.
    Clin Infect Dis, 44(9): 1229-34. [Abstract] [Full-text]
33. Syphilis and HIV infection: an update.
    Clin Infect Dis, 44(9): 1222-8. [Abstract] [Full-text]
34. HIV/AIDS in Pakistan: the battle begins.
    Retrovirology, 4: 22. [Abstract] [Full-text]
35. Male circumcision to prevent HIV transmission and acquisition: what else do we need to know?
    AIDS Behav, 11(3): 357-63. [Abstract] [Full-text]
36. Using theory to understand how interventions work: Project RESPECT, condom use, and the Integrative Model.
    AIDS Behav, 11(3): 393-407. [Abstract] [Full-text]
37. Knowledge of maternal HIV/AIDS and child adjustment: the moderating role of children's relationships with their mothers.
    AIDS Behav, 11(3): 409-20. [Abstract] [Full-text]
38. The stress moderating role of benefit finding on psychological distress and well-being among women living with HIV/AIDS.
    AIDS Behav, 11(3): 421-33. [Abstract] [Full-text]
39. Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV-infected individuals.
    AIDS Behav, 11(3): 385-92. [Abstract] [Full-text]
40. Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review.
    AIDS Behav, 11(3): 341-55. [Abstract] [Full-text]
41. Perceptions of community HIV prevalence, own HIV infection, and condom use among teachers in KwaZulu-Natal, South Africa.
    AIDS Behav, 11(3): 453-62. [Abstract] [Full-text]
42. A social cognitive model of health for HIV-positive adults receiving care in India.
    AIDS Behav, 11(3): 491-504. [Abstract] [Full-text]
43. A longitudinal study of adolescents with perinatally or transfusion acquired HIV infection: sexual knowledge, risk reduction self-efficacy and sexual behavior.
    AIDS Behav, 11(3): 471-8. [Abstract] [Full-text]
44. Mediational analysis in HIV/AIDS research: estimating multivariate path analytic models in a structural equation modeling framework.
    AIDS Behav, 11(3): 365-83. [Abstract] [Full-text]
45. Prevalence and correlates of condom use and HIV testing among female sex workers in Tashkent, Uzbekistan: implications for HIV transmission.
    AIDS Behav, 11(3): 435-42. [Abstract] [Full-text]
46. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy.
    J Thorac Oncol, 2(4): 268-72. [Abstract] [Full-text]
47. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration.
    J Neurosci, 27(14): 3703-11. [Abstract] [Full-text]
48. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.
    Blood, 109(8): 3351-9. [Abstract] [Full-text]
49. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
    Retrovirology, 4: 21. [Abstract] [Full-text]
50. Responding to the threat of HIV among persons with mental illness and substance abuse.
    Curr Opin Psychiatry, 20(3): 235-41. [Abstract] [Full-text]
51. HIV/AIDS risk reduction counseling for alcohol using sexually transmitted infections clinic patients in Cape Town, South Africa.
    J Acquir Immune Defic Syndr, 44(5): 594-600. [Abstract] [Full-text]
52. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.
    J Acquir Immune Defic Syndr, 44(5): 601-5. [Abstract] [Full-text]
53. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.
    J Acquir Immune Defic Syndr, 44(5): 506-17. [Abstract] [Full-text]
54. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors.
    J Acquir Immune Defic Syndr, 44(5): 569-77. [Abstract] [Full-text]
55. HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru.
    J Acquir Immune Defic Syndr, 44(5): 578-85. [Abstract] [Full-text]
56. Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings.
    J Acquir Immune Defic Syndr, 44(5): 525-30. [Abstract] [Full-text]
57. Hysterectomy among women with HIV: indications and incidence.
    J Acquir Immune Defic Syndr, 44(5): 566-8. [Abstract] [Full-text]
58. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.
    J Acquir Immune Defic Syndr, 44(5): 500-5. [Abstract] [Full-text]
59. Trends in HIV infection: prevention-related attitudes and behaviors among secondary school students in western Uganda.
    J Acquir Immune Defic Syndr, 44(5): 586-93. [Abstract] [Full-text]
60. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
    J Acquir Immune Defic Syndr, 44(5): 540-50. [Abstract] [Full-text]
61. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
    J Acquir Immune Defic Syndr, 44(5): 557-61. [Abstract] [Full-text]
62. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients.
    J Acquir Immune Defic Syndr, 44(5): 551-6. [Abstract] [Full-text]
63. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals.
    J Acquir Immune Defic Syndr, 44(5): 518-24. [Abstract] [Full-text]
64. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy.
    J Acquir Immune Defic Syndr, 44(5): 531-9. [Abstract] [Full-text]
65. Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.
    J Acquir Immune Defic Syndr, 44(5): 562-5. [Abstract] [Full-text]
66. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
    Lancet, 369(9568): 1169-78. [Abstract] [Full-text]
67. Neurobiology of HIV, psychiatric and substance abuse comorbidity research: workshop report.
    Brain Behav Immun, 21(4): 428-41. [Abstract] [Full-text]
68. Internalized stigma, discrimination, and depression among men and women living with HIV/AIDS in Cape Town, South Africa.
    Soc Sci Med, 64(9): 1823-31. [Abstract] [Full-text]
69. LNA derivatives of a kissing aptamer targeted to the trans-activating responsive RNA element of HIV-1.
    Blood Cells Mol Dis, 38(3): 204-9. [Abstract] [Full-text]
70. GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model.
    Vaccine, 25(17): 3293-301. [Abstract] [Full-text]
71. Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection.
    Drug Alcohol Depend, 88: S41-51. [Abstract] [Full-text]
72. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
    Vaccine, 25(17): 3277-83. [Abstract] [Full-text]
73. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004.
    Arch Intern Med, 167(7): 692-700. [Abstract] [Full-text]
74. Older age and the response to and tolerability of antiretroviral therapy.
    Arch Intern Med, 167(7): 684-91. [Abstract] [Full-text]
75. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
    Biochem J, 403(3): 565-71. [Abstract] [Full-text]
76. Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison.
    Am J Hematol, 82(5): 335-41. [Abstract] [Full-text]
77. Microarray multiplex assay for the simultaneous detection and discrimination of hepatitis B, hepatitis C, and human immunodeficiency type-1 viruses in human blood samples.
    Biochem Biophys Res Commun, 356(4): 1017-23. [Abstract] [Full-text]
78. The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct.
    Immunology, 121(1): 140-5. [Abstract] [Full-text]
79. Tutorial in biostatistics: competing risks and multi-state models.
    Stat Med, 26(11): 2389-430. [Abstract] [Full-text]
80. D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance.
    J Med Chem, 50(8): 1828-39. [Abstract] [Full-text]
81. Limitations of the human-PBL-SCID mouse model for vaginal transmission of HIV-1.
    Am J Reprod Immunol, 57(5): 353-60. [Abstract] [Full-text]
82. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses.
    Clin Microbiol Infect, 13(5): 510-5. [Abstract] [Full-text]
83. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Lancet, 369(9569): 1261-9. [Abstract] [Full-text]
84. HIV-1 infection of trophoblasts is independent of gp120/CD4 Interactions but relies on heparan sulfate proteoglycans.
    J Infect Dis, 195(10): 1461-71. [Abstract] [Full-text]
85. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection.
    J Infect Dis, 195(10): 1452-60. [Abstract] [Full-text]
86. Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication.
    J Infect Dis, 195(10): 1443-51. [Abstract] [Full-text]
87. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women.
    J Infect Dis, 195(10): 1437-42. [Abstract] [Full-text]
88. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    J Infect Dis, 195(10): 1426-36. [Abstract] [Full-text]
89. Antiretroviral therapy for HIV-1-infected children in Haiti.
    J Infect Dis, 195(10): 1411-8. [Abstract] [Full-text]
90. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    J Infect Dis, 195(10): 1402-10. [Abstract] [Full-text]
91. Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary tuberculosis: feasibility and costs.
    J Public Health Manag Pract, 13(3): 252-62. [Abstract] [Full-text]
92. A "Community Manifesto" for gay and bisexual men: an appeal to control HIV/STDs.
    J Public Health Manag Pract, 13(3): 244-51. [Abstract] [Full-text]
93. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    J Public Health Manag Pract, 13(3): 239-43. [Abstract] [Full-text]
94. Predictors of dual method use for pregnancy and HIV prevention among adolescent South African women.
    Contraception, 75(5): 383-9. [Abstract] [Full-text]
95. Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
    J Pharm Biomed Anal, 44(1): 188-95. [Abstract] [Full-text]
96. Children, AIDS and the politics of orphan care in Ethiopia: the extended family revisited.
    Soc Sci Med, 64(10): 2058-69. [Abstract] [Full-text]
97. HIV resistance and the developing world.
    Int J Antimicrob Agents, 29(5): 510-7. [Abstract] [Full-text]
98. Evidence against a direct antiviral activity of the proteasome during the early steps of HIV-1 replication.
    Virology, 361(1): 1-8. [Abstract] [Full-text]
99. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
    J Biol Chem, 282(16): 11667-75. [Abstract] [Full-text]
100. CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease.
     Virology, 361(1): 34-44. [Abstract] [Full-text]
101. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
     Virology, 361(1): 212-28. [Abstract] [Full-text]
102. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques.
     Virology, 361(1): 68-79. [Abstract] [Full-text]
103. HIV prevalence and poverty in Africa: micro- and macro-econometric evidences applied to Burkina Faso.
     J Health Econ, 26(3): 483-504. [Abstract] [Full-text]
104. An HIV-preventive intervention for youth living with HIV.
     Behav Modif, 31(3): 345-63. [Abstract] [Full-text]
105. Mechanisms of ischemic stroke in HIV-infected patients.
     Neurology, 68(16): 1257-61. [Abstract] [Full-text]
106. Impaired reinnervation in HIV infection following experimental denervation.
     Neurology, 68(16): 1251-6. [Abstract] [Full-text]
107. Impact of hepatitis C on HIV progression in adults with alcohol problems.
     Alcohol Clin Exp Res, 31(5): 829-36. [Abstract] [Full-text]
108. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.
     J Exp Med, 204(4): 705-14. [Abstract] [Full-text]
109. Stable gene expression occurs from a minority of integrated HIV-1-based vectors: transcriptional silencing is present in the majority.
     Gene Ther, 14(9): 741-51. [Abstract] [Full-text]
110. Lentivirus-mediated gene transfer to the rat, ovine and human cornea.
     Gene Ther, 14(9): 760-7. [Abstract] [Full-text]
111. Bronchoalveolar neutrophils, interferon gamma-inducible protein 10 and interleukin-7 in AIDS-associated tuberculosis.
     Clin Exp Immunol, 148(2): 254-9. [Abstract] [Full-text]
112. HIV/AIDS support and African pentecostalism: the case of the Redeemed Christian Church of God (RCCG).
     J Health Psychol, 12(3): 475-84. [Abstract] [Full-text]
113. 'Dying twice': a multi-level model of the roots of AIDS stigma in two South African communities.
     J Health Psychol, 12(3): 403-16. [Abstract] [Full-text]
114. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.
     Proc Natl Acad Sci U S A, 104(16): 6776-81. [Abstract] [Full-text]
115. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef.
     Proc Natl Acad Sci U S A, 104(16): 6812-7. [Abstract] [Full-text]
116. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
117. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
118. Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
119. Associations of patient health-related problem solving with disease control, emergency department visits, and hospitalizations in HIV and diabetes clinic samples.
     J Gen Intern Med, 22(5): 649-54. [Abstract] [Full-text]
120. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
     Retrovirology, 4: 25. [Abstract] [Full-text]
121. Drug-resistant genital tuberculosis of the penis in a human immunodeficiency virus non-reactive individual.
     J Med Microbiol, 56: 694-5. [Abstract] [Full-text]
122. Effect of intensive handwashing in the prevention of diarrhoeal illness among patients with AIDS: a randomized controlled study.
     J Med Microbiol, 56: 659-63. [Abstract] [Full-text]
123. Relationship between psychiatric status and frontal-subcortical systems in HIV-infected individuals.
     J Int Neuropsychol Soc, 13(3): 549-54. [Abstract] [Full-text]
124. Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment.
     J Int Neuropsychol Soc, 13(3): 462-70. [Abstract] [Full-text]
125. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya.
     Trop Med Int Health, 12(5): 687-94. [Abstract] [Full-text]
126. Early growth of infants of HIV-infected and uninfected Zambian women.
     Trop Med Int Health, 12(5): 594-602. [Abstract] [Full-text]
127. Carotid intima-media thickness in HIV patients treated with antiretroviral therapy.
     Clin Physiol Funct Imaging, 27(3): 173-9. [Abstract] [Full-text]
128. Efficient induction of HIV-1 replication in latently infected cells through contact with CD4+ T cells: involvement of NF-kappaB activation.
     Virology, 361(2): 325-34. [Abstract] [Full-text]
129. Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions.
     Virology, 361(2): 465-71. [Abstract] [Full-text]
130. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
     Antiviral Res, 75(1): 58-63. [Abstract] [Full-text]
131. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.
     Antiviral Res, 75(1): 75-82. [Abstract] [Full-text]
132. Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors.
     Epidemiol Infect, 135(4): 592-603. [Abstract] [Full-text]
133. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.
     J Clin Gastroenterol, 41(5): 484-90. [Abstract] [Full-text]
134. Reduced computed tomography radiation dose in HIV-related pneumonia: effect on diagnostic image quality.
     Clin Imaging, 31(3): 178-84. [Abstract] [Full-text]
135. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
     Cell, 129(2): 263-75. [Abstract] [Full-text]
136. Targeting the sticky fingers of HIV-1.
     Cell, 129(2): 243-5. [Abstract] [Full-text]
137. Oral lesions in HIV-positive dental patients--one more argument for tobacco smoking cessation.
     Oral Dis, 13(3): 324-8. [Abstract] [Full-text]
138. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV.
     J Eur Acad Dermatol Venereol, 21(5): 596-601. [Abstract] [Full-text]
139. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
     Vaccine, 25(19): 3809-15. [Abstract] [Full-text]
140. A simple competitive RT-PCR assay for quantitation of HIV-1 subtype B and non-B RNA in plasma.
     J Virol Methods, 142(1): 113-7. [Abstract] [Full-text]
141. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.
     Antimicrob Agents Chemother, 51(5): 1770-9. [Abstract] [Full-text]
142. Mechanisms that prevent template inactivation by HIV-1 reverse transcriptase RNase H cleavages.
     J Biol Chem, 282(17): 12598-609. [Abstract] [Full-text]
143. A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region.
     J Virol Methods, 142(1): 127-35. [Abstract] [Full-text]
144. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
     Vaccine, 25(19): 3841-50. [Abstract] [Full-text]
145. Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.
     Antimicrob Agents Chemother, 51(5): 1780-6. [Abstract] [Full-text]
146. Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.
     Antimicrob Agents Chemother, 51(5): 1596-607. [Abstract] [Full-text]
147. Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers?
     Virus Res, 125(2): 119-34. [Abstract] [Full-text]
148. FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection.
     Blood, 109(9): 3786-93. [Abstract] [Full-text]
149. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study.
     Blood, 109(9): 3667-71. [Abstract] [Full-text]
150. Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leukocyte chemotaxis and receptor internalization.
     Blood, 109(9): 3633-9. [Abstract] [Full-text]
151. Trapping and apoptosis of novel subsets of memory T lymphocytes expressing CCR6 in the spleen of HIV-infected patients.
     Blood, 109(9): 3649-57. [Abstract] [Full-text]
152. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV).
     Blood, 109(9): 3873-80. [Abstract] [Full-text]
153. HIV-1 immunopathogenesis: how good interferon turns bad.
     Clin Immunol, 123(2): 121-8. [Abstract] [Full-text]
154. 'If I had my residency I wouldn't worry': negotiating migration and HIV in Sydney, Australia.
     Ethn Health, 12(3): 205-25. [Abstract] [Full-text]
155. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53.
     J Cell Biol, 177(2): 329-41. [Abstract] [Full-text]
156. Pattern of neuropsychological performance among HIV positive patients in Uganda.
     BMC Neurol, 7: 8. [Abstract] [Full-text]
157. Evaluation of the growth inhibitory activities of Triphala against common bacterial isolates from HIV infected patients.
     Phytother Res, 21(5): 476-80. [Abstract] [Full-text]
158. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.
     J Cereb Blood Flow Metab, 27(5): 1033-42. [Abstract] [Full-text]
159. Childhood sexuality and rights in the context of HIV/AIDS.
     Cult Health Sex, 9(3): 309-24. [Abstract] [Full-text]
160. Don't bother to wrap it: online Giftgiver and Bugchaser newsgroups, the social impact of gift exchanges and the 'carnivalesque'.
     Cult Health Sex, 9(3): 277-92. [Abstract] [Full-text]
161. 'It's really a hard life': love, gender and HIV risk among male-to-female transgender persons.
     Cult Health Sex, 9(3): 233-45. [Abstract] [Full-text]
162. HIV incidence and recent injections among adults in rural southwestern Uganda.
     AIDS, 21(8): 1056-8. [Abstract] [Full-text]
163. HIV-1 co-infection prevalence in two cohorts of early HIV-1 seroconverters in France.
     AIDS, 21(8): 1055-6. [Abstract] [Full-text]
164. Steady-state lopinavir levels in third trimester of pregnancy.
     AIDS, 21(8): 1053-4. [Abstract] [Full-text]
165. HIV-1 genetic diversity and compartmentalization in mother/infant pairs infected with CRF01_AE.
     AIDS, 21(8): 1050-3. [Abstract] [Full-text]
166. Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control.
     AIDS, 21(8): 1048-50. [Abstract] [Full-text]
167. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study).
     AIDS, 21(8): 1043-5. [Abstract] [Full-text]
168. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.
     AIDS, 21(8): 1035-9. [Abstract] [Full-text]
169. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe.
     AIDS, 21(8): 1027-34. [Abstract] [Full-text]
170. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland.
     AIDS, 21(8): 1019-26. [Abstract] [Full-text]
171. Trends in HIV prevalence in blood donations in Europe, 1990-2004.
     AIDS, 21(8): 1011-8. [Abstract] [Full-text]
172. Microalbuminuria in HIV infection.
     AIDS, 21(8): 1003-9. [Abstract] [Full-text]
173. Twin pregnancy as a risk factor for mother-to-child transmission of HIV-1: trends over 20 years.
     AIDS, 21(8): 993-1002. [Abstract] [Full-text]
174. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours.
     AIDS, 21(8): 983-91. [Abstract] [Full-text]
175. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
     AIDS, 21(8): 973-82. [Abstract] [Full-text]
176. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
     AIDS, 21(8): 965-71. [Abstract] [Full-text]
177. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
     AIDS, 21(8): 957-64. [Abstract] [Full-text]
178. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
     AIDS, 21(8): 947-55. [Abstract] [Full-text]
179. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
     AIDS, 21(8): 939-46. [Abstract] [Full-text]
180. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
     AIDS, 21(8): 929-38. [Abstract] [Full-text]
181. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children.
     AIDS, 21(8): 921-7. [Abstract] [Full-text]
182. Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1.
     AIDS, 21(8): 905-9. [Abstract] [Full-text]
183. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
     Ann Clin Biochem, 44: 219-31. [Abstract] [Full-text]
184. Niacin nutritional status in HIV type 1-positive children: preliminary data.
     J Pediatr Gastroenterol Nutr, 44(5): 629-33. [Abstract] [Full-text]
185. Class of antiretroviral drugs and the risk of myocardial infarction.
     N Engl J Med, 356(17): 1723-35. [Abstract] [Full-text]
186. Exploiting the defensive sugars of HIV-1 for drug and vaccine design.
     Nature, 446(7139): 1038-45. [Abstract] [Full-text]
187. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa?
     J Acquir Immune Defic Syndr, 45(1): 115-22. [Abstract] [Full-text]
188. Successful introduction of routine opt-out HIV testing in antenatal care in Botswana.
     J Acquir Immune Defic Syndr, 45(1): 102-7. [Abstract] [Full-text]
189. Prevalence of and risk factors for pubic lipoma development in HIV-infected persons.
     J Acquir Immune Defic Syndr, 45(1): 72-6. [Abstract] [Full-text]
190. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
     J Acquir Immune Defic Syndr, 45(1): 52-9. [Abstract] [Full-text]
191. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
     J Acquir Immune Defic Syndr, 45(1): 34-42. [Abstract] [Full-text]
192. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
     J Acquir Immune Defic Syndr, 45(1): 4-8. [Abstract] [Full-text]
193. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.
     J Med Chem, 50(9): 2225-39. [Abstract] [Full-text]
194. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.
     J Acquir Immune Defic Syndr, 45(1): 43-51. [Abstract] [Full-text]
195. Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection.
     J Acquir Immune Defic Syndr, 45(1): 9-19. [Abstract] [Full-text]
196. Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women.
     J Acquir Immune Defic Syndr, 45(1): 60-5. [Abstract] [Full-text]
197. Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles.
     J Virol, 81(10): 5155-65. [Abstract] [Full-text]
198. Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion.
     J Virol, 81(10): 5294-304. [Abstract] [Full-text]
199. Novel nuclear import of Vpr promoted by importin alpha is crucial for human immunodeficiency virus type 1 replication in macrophages.
     J Virol, 81(10): 5284-93. [Abstract] [Full-text]
200. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker.
     J Virol, 81(10): 5000-13. [Abstract] [Full-text]
201. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.
     J Virol, 81(10): 5225-37. [Abstract] [Full-text]
202. Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.
     J Virol, 81(10): 5413-7. [Abstract] [Full-text]
203. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.
     J Virol, 81(10): 5325-30. [Abstract] [Full-text]
204. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.
     J Virol, 81(10): 5257-69. [Abstract] [Full-text]
205. Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.
     J Virol, 81(10): 5375-84. [Abstract] [Full-text]
206. Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells.
     J Virol, 81(10): 4973-80. [Abstract] [Full-text]
207. The influence of social and sexual networks in the spread of HIV and syphilis among men who have sex with men in Shanghai, China.
     J Acquir Immune Defic Syndr, 45(1): 77-84. [Abstract] [Full-text]
208. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study.
     J Acquir Immune Defic Syndr, 45(1): 85-92. [Abstract] [Full-text]
209. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort.
     J Acquir Immune Defic Syndr, 45(1): 28-33. [Abstract] [Full-text]
210. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
     J Virol, 81(10): 5331-8. [Abstract] [Full-text]
211. A comparison of factors associated with prevalent diabetes mellitus among HIV-Infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort.
     J Acquir Immune Defic Syndr, 45(1): 66-71. [Abstract] [Full-text]
212. Differences in HIV care between patients with and without severe mental illness.
     Psychiatr Serv, 58(5): 681-8. [Abstract] [Full-text]
213. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians.
     Hum Immunol, 68(5): 454-61. [Abstract] [Full-text]
214. Monotherapy with lopinavir/ritonavir.
     Expert Opin Investig Drugs, 16(5): 735-41. [Abstract] [Full-text]
215. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
     J Virol, 81(10): 5144-54. [Abstract] [Full-text]
216. Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production.
     J Virol, 81(10): 5121-31. [Abstract] [Full-text]
217. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS.
     Am J Epidemiol, 165(10): 1143-53. [Abstract] [Full-text]
218. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.
     Am J Epidemiol, 165(10): 1134-42. [Abstract] [Full-text]
219. Prejudice towards chronic diseases: comparison among epilepsy, AIDS and diabetes.
     Seizure, 16(4): 320-3. [Abstract] [Full-text]
220. Detection of pulmonary Mycoplasma pneumoniae infections in HIV-infected subjects using culture and serology.
     Int J Infect Dis, 11(3): 232-8. [Abstract] [Full-text]
221. Bacteremia in adult patients with acquired immunodeficiency syndrome in the northeast of Thailand.
     Int J Infect Dis, 11(3): 226-31. [Abstract] [Full-text]
222. Children with sickle cell disease and human immunodeficiency virus-1 infection: use of inpatient care services in the United States.
     Pediatr Infect Dis J, 26(5): 406-10. [Abstract] [Full-text]
223. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study.
     Lancet, 369(9571): 1440-51. [Abstract] [Full-text]
224. A clathrin, caveolae, and dynamin-independent endocytic pathway requiring free membrane cholesterol drives HIV-1 internalization and infection in polarized trophoblastic cells.
     J Mol Biol, 368(5): 1267-83. [Abstract] [Full-text]
225. Regulation of topoisomerase II alpha and beta in HIV-1 infected and uninfected neuroblastoma and astrocytoma cells: involvement of distinct nordihydroguaretic acid sensitive inflammatory pathways.
     Arch Biochem Biophys, 461(1): 40-9. [Abstract] [Full-text]
226. Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication.
     J Biol Chem, 282(18): 13456-67. [Abstract] [Full-text]
227. Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes.
     J Biol Chem, 282(18): 13617-26. [Abstract] [Full-text]
228. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.
     J Biol Chem, 282(18): 13141-5. [Abstract] [Full-text]
229. Primary intraosseous Kaposi's sarcoma presenting as an asymptomatic periapical radiolucency: a case report.
     Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103(5): e65-70. [Abstract] [Full-text]
230. Retro-transduction by virus pseudotyped with glycoprotein of vesicular stomatitis virus.
     Virology, 362(1): 131-8. [Abstract] [Full-text]
231. HIV-1 integration is inhibited by stimulation of the VPAC2 neuroendocrine receptor.
     Virology, 362(1): 38-49. [Abstract] [Full-text]
232. Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening.
     Virology, 362(1): 16-25. [Abstract] [Full-text]
233. Differential gene expression in CD8(+) cells from HIV-1-infected subjects showing suppression of HIV replication.
     Virology, 362(1): 217-25. [Abstract] [Full-text]
234. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
     Virology, 362(1): 163-78. [Abstract] [Full-text]
235. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells.
     Virology, 362(1): 67-74. [Abstract] [Full-text]
236. Random changepoint modelling of HIV immunologic responses.
     Stat Med, 26(9): 2074-87. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.